Perioperative treatment of gastrointestinal stromal tumors

ONCOLOGY

Volumn 23, Issue 1, 2009, Pages 54-61

  Dos Santos Fernandes, Gustavo ^a   Blanke, Charles D ^b   Freitas, Daniela ^a   Guedes, Rodrigo ^a   Hoff, Paulo M ^c  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KIT; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER INHIBITION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC ERROR; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; LEIOMYOSARCOMA; METASTASIS POTENTIAL; MITOSIS; MUTATIONAL ANALYSIS; NAUSEA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PATIENT SAFETY; PERIOPERATIVE PERIOD; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PREOPERATIVE CARE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; PROTO ONCOGENE; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; STOMACH CANCER; SURGICAL RISK; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MUTATION; NEOADJUVANT THERAPY; PHARMACOGENETICS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 61449201401     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Int J Surg Pathol 10:81-89, 2002.
2. Mazur MT, Clark HB: Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7:507-519, 1983.
3. Nishida T, Hirota S, Taniguchi M, et al: Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 19:323-324, 1998.
4. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998.
5. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003.
6. van Oosterom AT, Verweij J: New drugs for the treatment of sarcomas. Hematol Oncol Clin North Am 9:909-925, 1995.
7. Joensuu H: Gastrointestinal stromal tumor (GIST). Ann Oncol 17(suppl 10):x280-286, 2006.
8. Tryggvason G, Gislason HG, Magnusson MK, et al: Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117:289-293, 2005.
9. Nilsson B, Bumming P, Meis-Kindblom JM, et al: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103:821-829, 2005.
10. Kawanowa K, Sakuma Y, Sakurai S, et al: High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37:1527-1535, 2006.
11. Tran T, Davila JA, El-Serag HB: The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 100:162-168, 2005.
12. DeMatteo RP, Gold JS, Saran L, et al: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608-615, 2008.
13. Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52-68, 2005.
14. Miettinen M, Makhlouf H, Sobin LH, et al: Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30:477-489, 2006.
15. Miettinen M, Lasota J: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83, 2006.
16. Emory TS, Sobin LH, Lukes L, et al: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site. Am J Surg Pathol 23:82-87, 1999.
17. Huang HY, Li CF, Huang WW, et al: A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: A subdivision of the original high-risk group on the basis of outcome. Surgery 141:748-756, 2007.
18. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465, 2002.
19. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002.
20. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006.
21. Tuveson DA, Willis NA, Jacks T, et al: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20:5054-5058, 2001.
22. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001.
23. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001.
24. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002.
25. Blanke CD, Demetri GD, von Mehren M, et al: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625, 2008.
26. Blay JY, Le Cesne A, Ray-Coquard I, et al: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 25:1107-1113, 2007.
27. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008.
28. Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757, 2005.
29. Van Glabbeke MM, Owzar K, Rankin C, et al: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A metaanalyis based on 1,640 patients (pts) (abstract 10004). J Clin Oncol 25(18S):546s, 2007.
30. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003.
31. Heinrich MC, Corless CL, Blanke CD, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764-4774, 2006.
32. Verweij J, Casali PG, Zaleberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004.
33. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006.
34. Patel S, Zalcberg JR: Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials. Eur J Cancer 44:501-509, 2008.
35. Corless CL, Schroeder A, Griffith D, et al: PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357-5364, 2005.
36. Husband JE, Schwartz LH, Spencer J, et al: Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 90:2256-2260, 2004.
37. Antoch G, Kanja J, Bauer S, et al: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357-365, 2004.
38. Stroobants S, Goeminne J, Seegers M, et al: 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012-2020, 2003.
39. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007.
40. Benjamin RS, Choi H, Macapinlac HA, et al: We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-1764, 2007.
41. Buemming P, Meis-Kindblom JM, Kindblom LG, et al: Is there an indication for adjuvant treatment with imatinib mesylate in patients with aggressive gastrointestinal stromal tumors (GISTs) (abstract 3289)? Proc Am Soc Clin Oncol 22:818, 2003.
42. Nilsson BE, Bumming P, Meis-Kindblom JM, et al: Treatment of gastrointestinal stromal tumors GISTs) with imatinib in neoadjuvant, adjuvant and palliative settings, a centre-based study of 17 patients (abstract 3337). Proc Am Soc Clin Oncol 22:830, 2003.
43. Dematteo RP, Antonescu CR, Chadaram V, et al: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000 (abstract 9009). J Clin Oncol 23:818s, 2005.
44. DeMatteo RP, Owzar K, Antonescu CR, et al: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 (abstract 8). Presented at the 2008 Gastrointestinal Cancers Symposium; Orlando, Fla; Jan 25-27, 2008.
45. Zhan WH, for the China Gastrointestinal Cooperative Group: Efficacy and safety of adjuvanc post-surgical therapy with imatinib in patients with high risk of relapsing GIST (abstract 10045). J Clin Oncol 25:556s, 2007.
46. DeMatteo R, Owzar K, Maki R, et al: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001 (abstract 10079). Presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, June 1-5, 2007. Available at www.asco.org. Accessed December 4, 2008.
47. Gold JS, Dematteo RP: Combined surgical and molecular therapy: The gastrointestinal stromal tumor model. Ann Surg 244:176-184, 2006.
48. Hasegawa J, Kanda T, Hirota S, et al: Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 12:212-217, 2007.
49. Bonvalot S, Eldweny H, Pechoux CL, et al: Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13:1596-1603, 2006.
50. DeMatteo RP, Maki RG, Singer S, et al: Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347-352, 2007.
51. Rutkowski P, Nowecki Z, Nyckowski P, et al: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93:304-311, 2006.
52. Raut CP, Posner M, Desai J, et al: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325-2331, 2006.
53. Al-Batran SE, Hartmann JT, Heidel F, et al: Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: A three-center-based study of 38 patients. Gastric Cancer 10:145-152, 2007.
54. Andtbacka RH, Ng CS, Scaife CL, et al: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14:14-24, 2007.
55. Pantaleo MA, Di Battista M, Catena F, et al: Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol 134:625-630, 2008.
56. Joensuu H: Sunitinib for imatinib-resistant GIST. Lancet 368:1303-1304, 2006.
57. Scaife CL, Hunt KK, Patel SR, et al: Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 186:665-669, 2003.
58. Eisenberg BL, Harris J, Blanke C, et al: Phase II trial of neoadjuvant/ adjuvant imatinib mesylate (IM) for advanced primary and recurrent operable GI stromal tumor (GIST) - early results of RTOG 0132 (abstract 80). Presented at the Society of Surgical Oncology's 61st Annual Cancer Symposium; Chicago; March 13-16, 2008.
59. de Vos tot Nederveen Cappel RJ, van Hillegersberg R, Rodenhuis S, et al: Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib. Dig Surg 21:77-79, 2004.
60. Katz D, Segal A, Alberton Y, et al: Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 15:599-602, 2004.
61. Cavaliere D, Vagliasindi A, Mura G, et al: Downstaging of a gastric GIST by neoadjuvant imatinib and endoscopic assisted laparoscopic resection. Eur J Surg Oncol 33:1044-1046, 2007.
62. Shah JN, Sun W, Seethala RR, et al: Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. Gastrointest Endosc 61:625-627, 2005.
63. Gronchi A, Fiore M, Miselli F, et al: Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 245:341-346, 2007.
64. Loughrey MB, Mitchell C, Mann GB, et al: Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58:779-781, 2005.